Benzinga Pro data, Agile Therapeutics AGRX reported Q3 sales of $3.00 million. Earnings fell to a loss of $19.67 million, resulting in a 60.95% decrease from last quarter. In Q2, Agile Therapeutics brought in $2.13 million in sales but lost $12.22 million in earnings.
What Is ROCE?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Agile Therapeutics posted an ROCE of -3.14%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Agile Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Agile Therapeutics, a negative ROCE ratio of -3.14% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Upcoming Earnings Estimate
Agile Therapeutics reported Q3 earnings per share at $-0.23/share, which beat analyst predictions of $-0.29/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.